Cancer drug combo trial halted early: what it means for patients
NCT ID NCT04276376
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tested a combination of two drugs (rucaparib and atezolizumab) in 130 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94800, France
Conditions
Explore the condition pages connected to this study.